Riha Vaidya

1.4k total citations · 1 hit paper
41 papers, 889 citations indexed

About

Riha Vaidya is a scholar working on Economics and Econometrics, Oncology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Riha Vaidya has authored 41 papers receiving a total of 889 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Economics and Econometrics, 18 papers in Oncology and 11 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Riha Vaidya's work include Health Systems, Economic Evaluations, Quality of Life (21 papers), Economic and Financial Impacts of Cancer (17 papers) and Ethics in Clinical Research (8 papers). Riha Vaidya is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (21 papers), Economic and Financial Impacts of Cancer (17 papers) and Ethics in Clinical Research (8 papers). Riha Vaidya collaborates with scholars based in United States, India and United Kingdom. Riha Vaidya's co-authors include Joseph M. Unger, Dawn L. Hershman, Mark E. Fleury, Lori M. Minasian, Cathee Till, Raymond U. Osarogiagbon, Michael LeBlanc, Hong Xiao, Charles D. Blanke and Gilberto Levy and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

Riha Vaidya

36 papers receiving 878 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical, and Physician and Patient Barriers to Cancer Clinical Trial Participation

2018 343 citations Joseph M. Unger, Riha Vaidya et al. JNCI Journal of the National Cancer Institute profile →

Peers

Riha Vaidya

PHEOH

ONCOL

GHP

PHYSI

Caroline Schenkel United States

Lynn Howie United States

Reka Pataky Canada

Patricia Commiskey United States

Ateesha F. Mohamed United States

Ann Culkin United States

Kerin B. Adelson United States

Lawson Eng Canada

Elena Springall Canada

Christopher A. Zeruto United States

Caroline Schenkel United States

Riha Vaidya

340 ×0.8

PHEOH

343 ×1.0

452 ×2.1

ONCOL

144 ×0.9

GHP

70 ×0.6

PHYSI

Citations per year, relative to Riha Vaidya Riha Vaidya (= 1×) peers Caroline Schenkel

Countries citing papers authored by Riha Vaidya

Since Specialization

Citations

This map shows the geographic impact of Riha Vaidya's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Riha Vaidya with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Riha Vaidya more than expected).

Fields of papers citing papers by Riha Vaidya

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Riha Vaidya. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Riha Vaidya. The network helps show where Riha Vaidya may publish in the future.

Co-authorship network of co-authors of Riha Vaidya

This figure shows the co-authorship network connecting the top 25 collaborators of Riha Vaidya. A scholar is included among the top collaborators of Riha Vaidya based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Riha Vaidya. Riha Vaidya is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Saeed, Anwaar, Paul E. Oberstein, Dan G. Duda, et al.. (2025). S2303: phase II/III trial of paclitaxel + ramucirumab ± nivolumab in gastric and esophageal adenocarcinoma (PARAMUNE). Future Oncology. 21(11). 1325–1331.

Gupta, Arjun, Cathee Till, Riha Vaidya, Dawn L. Hershman, & Joseph M. Unger. (2025). Health Care Contact Days for Older Adults Enrolled in Cancer Clinical Trials. JAMA Network Open. 8(3). e250778–e250778. 4 indexed citations

Unger, Joseph M., Cathee Till, Catherine M. Tangen, et al.. (2024). Long-Term Adverse Effects and Complications After Prostate Cancer Treatment. JAMA Oncology. 10(12). 1654–1654. 9 indexed citations

Hershman, Dawn L., Riha Vaidya, Cathee Till, et al.. (2024). Socioeconomic Deprivation and Health Care Use in Patients Enrolled in SWOG Cancer Clinical Trials. JAMA Network Open. 7(3). e244008–e244008. 5 indexed citations

Xiao, Hong, Riha Vaidya, Dawn L. Hershman, & Joseph M. Unger. (2024). Impact of Broadening Trial Eligibility Criteria on the Inclusion of Patients With Brain Metastases in Cancer Clinical Trials: Time Series Analyses for 2012-2022. Journal of Clinical Oncology. 42(16). 1953–1960. 10 indexed citations

Presant, Cary A., Cathee Till, Riha Vaidya, et al.. (2024). Smoking prevalence and association with sociodemographic variables in cancer clinical trial participants. Cancer. 131(1). e35560–e35560. 1 indexed citations

Unger, Joseph M., Hong Xiao, Riha Vaidya, & Michael LeBlanc. (2024). Patient Enrollment to Industry-Sponsored Versus Federally-Sponsored Cancer Clinical Trials. Journal of Clinical Oncology. 42(33). 3917–3925. 11 indexed citations

Vaidya, Riha, Cathee Till, N. Lynn Henry, et al.. (2024). Neighborhood socioeconomic deprivation and patient-reported outcomes in symptom management trials for women with breast cancer. Breast Cancer Research and Treatment. 209(3). 603–611.

Unger, Joseph M., et al.. (2024). The cost of doing business: Drug costs in federally sponsored cancer clinical trials.. JCO Oncology Practice. 20(10_suppl). 10–10.

10.

Unger, Joseph M., Riha Vaidya, Michael Fisch, et al.. (2024). Patient-reported fatigue and risk of treatment-related adverse events (AEs) in patients receiving systemic therapy in cancer clinical trials.. Journal of Clinical Oncology. 42(16_suppl). 11015–11015.

11.

Lee, Shing M., Weijia Fan, Aijin Wang, et al.. (2023). Novel Approaches for Dynamic Visualization of Adverse Event Data in Oncology Clinical Trials: A Case Study Using Immunotherapy Trial S1400-I (SWOG). JCO Clinical Cancer Informatics. 7(7). e2200165–e2200165. 2 indexed citations

12.

Vaidya, Riha, Joseph M. Unger, Katherine Minichiello, et al.. (2023). Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP). JCO Precision Oncology. 7(7). e2300218–e2300218. 1 indexed citations

13.

Watabayashi, Kate, Deborah Delaney, Ruth C. Carlos, et al.. (2023). Assessment of financial screening and navigation capabilities at National Cancer Institute community oncology clinics. JNCI Cancer Spectrum. 7(5). 10 indexed citations

14.

Vaidya, Riha, Amy K. Darke, Krishna S. Gunturu, et al.. (2023). Examining uptake of electronic patient reported outcomes (ePRO) in a prospective study of immune-related adverse events (IR-AEs).. JCO Oncology Practice. 19(11_suppl). 368–368. 1 indexed citations

15.

Amengual, Jennifer E., Patrick M. Reagan, Hayder Saeed, et al.. (2023). S2207: RANDOMIZED PHASE II STUDY OF THE ADDITION OF TARGETED AGENTS TO TAFASITAMAB‐LENALIDOMIDE IN TRANSPLANT INELIGIBLE PATIENTS WITH RELAPSED/REFRACTORY LBCL. Hematological Oncology. 41(S2). 842–843. 1 indexed citations

16.

Ellis, Shellie D., Riha Vaidya, Joseph M. Unger, et al.. (2022). Access to urologists for participation in research: An analysis of NCI's Community Oncology Research Program landscape survey. Contemporary Clinical Trials Communications. 29. 100981–100981. 2 indexed citations

17.

Hershman, Dawn L., Cathee Till, Jason D. Wright, et al.. (2020). Healthcare utilization and cost of care in elderly breast cancer patients enrolled in SWOG clinical trials. Breast Cancer Research and Treatment. 181(2). 455–463. 5 indexed citations

18.

Unger, Joseph M., Dawn L. Hershman, Cathee Till, et al.. (2020). “When Offered to Participate”: A Systematic Review and Meta-Analysis of Patient Agreement to Participate in Cancer Clinical Trials. JNCI Journal of the National Cancer Institute. 113(3). 244–257. 152 indexed citations

19.

Hershman, Dawn L., Cathee Till, Jason D. Wright, et al.. (2019). Association of baseline cardiovascular risk factors and health care utilization and costs in elderly breast cancer patients enrolled in SWOG clinical trials.. Journal of Clinical Oncology. 37(15_suppl). 11508–11508. 1 indexed citations

20.

Nazareth, Irwin, D. D. Naik, Riha Vaidya, et al.. (2006). HARMFUL ALCOHOL USE IN GOA, INDIA, AND ITS ASSOCIATIONS WITH VIOLENCE: A STUDY IN PRIMARY CARE. Alcohol and Alcoholism. 42(2). 131–137. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact